Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Advances in PARP inhibitor use for metastatic breast cancer

Prof Hope Rugo - University of California, San Francisco, USA

Advances in PARP inhibitor use for metastatic breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Margetuximab for the treatment of HER2-positive breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Margetuximab for the treatment of HER2-positive breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced...

Dr Tira Tan - National Cancer Centre, Singapore

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer ( Dr Tira Tan - National Cancer Centre, Singapore )

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in...

Dr Johannes Ettl - Technical University, Munich, Germany

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer ( Dr Johannes Ettl - Technical University, Munich, Germany )

Ribociclib plus endocrine therapy improves survival in premenopausal patients...

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2...

Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer ( Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA )

Guiding treatment decisions through the use of molecular profiling in breast...

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Guiding treatment decisions through the use of molecular profiling in breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Managing metastatic breast cancer and beyond using PARP inhibitors

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Updates in metastatic and early-stage breast cancer

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors in metastatic breast cancer: Where are we now?

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus...

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive...

Prof Hope Rugo - University of California, San Francisco, USA

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies ( Prof Hope Rugo - University of California, San Francisco, USA )

More from ecancer